Table 1.

Baseline characteristics of 12-month MDS-UPDRS total progressors vs non-progressors.

Predictive feature	Progressors: Non-progressors (PPMI)	P-value	Progressors: Non-progressors (PDBP)	P-value
Demographics	64%: 36%	-	48%:52%	-
Sample size (n)	529	-	350	-
Age (years)	61.9 ± 0.5: 62.1 ± 0.61	0.033	59.4 ± 1.15: 60.0 ± 1.01	0.034
Sex (%F)	24%: 22%	-	60%: 73%	-
Treatment status (%)
Levodopa	14% ± 0.02: 19% ± 0.03	0.312	75% ± 0.03: 76% ± 0.03	0.856
Dopamine agonist	10% ± 0.02: 13% ± 0.02	0.563	55% ± 0.04: 50% ± 0.04	0.434
Other PD medication	14% ± 0.02: 18% ± 0.03	0.479	74% ± 0.03: 74% ± 0.03	0.932
Clinical instruments
MDS-UPDRS I	4.1 ± 0.26: 4.6 ± 0.36	0.204	4.1 ± 0.39: 4.6 ± 0.43	0.566
MDS-UPDRS II	3.5 ± 0.25: 4.2 ± 0.34	0.043	4.7 ± 0.5: 5.6 ± 0.56	0.355
MDS-UPDRS III	15.9 ± 0.53: 21.0 ± 0.73	<0.001	19.1 ± 0.94: 24.4 ± 1.05	<0.001
MDS-UPDRS Total	23.6 ± 0.8: 29.9 ± 1.07	<0.001	28.0 ± 1.51: 34.8 ± 1.71	0.002
Hoehn & Yahr	1.5 ± 0.03: 1.7 ± 0.04	<0.001	2.03 ± 0.04: 2.1 ± 0.05	0.415
SE-ADL	94.0 ± 0.42: 93.7 ± 0.52	0.478	88.5 ± 0.93: 87.4 ± 1.02	0.568
MoCA	27.1 ± 0.15: 27.2 ± 0.2	0.013	26.0 ± 0.24: 26.1 ± 0.25	0.628
ESS
DaTScan neuroimaging
sbr_caudate_r	2.1 ± 0.04: 2.0 ± 0.06	0.06	-	-
sbr_caudate_l	2.1 ± 0.04: 2.0 ± 0.06	0.048	-	-
sbr_putamen_r	0.9 ± 0.03: 0.9 ± 0.05	0.02	-	-
sbr_putamen_l	0.9 ± 0.03: 0.9 ± 0.05	0.018	-	-
Genetics
Parkinson’s disease PRS (ave)	0.004 ± 0.0: 0.005 ± 0.0	0.229	0.0026 ± 0.0: 0.0025 ± 0.0	0.534
Educational attainment PRS (ave)	0.0005 ± 0.0: 0.0004 ± 0.0	0.594	0.0005 ± 0.0: 0.0004 ± 0.0	0.091
Monogenic risk (%)	32%: 40%	-	9%: 9%	-

Features consistently different between progressors and non-progressors in both PPMI and PDBP are bolded. See Supplemental Tables 2–3 for a more detailed comparison. All comparisons are made with the non-parametric Wilcoxon rank sums test.